Exosomes as a platform for ‘liquid biopsy’ in pancreatic cancer
Convergent Science Physical Oncology · 2017
DOI: 10.1088/2057-1739/aa5beb ↗Kurz gefasst
Fachartikel in der Zeitschrift Convergent Science Physical Oncology, 2017. Verfasst von Antonios Chronopoulos und 2 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: European Research Council.
Abstract (Originalsprache)
The dismal prognosis of pancreatic cancer has motivated research into identifying non-invasive ‘liquid biopsy’ biomarkers for early detection when treatment is most effective. Recently, exosomes—nanoscale membranous vesicles shed from tumour cells and which can be found circulating in the blood (and most bodily fluids)—have been discovered to contain a wealth of proteomic and genetic information, showing promise for pre-symptomatic screening and monitoring of disease. Here we examine recent findings highlighting the diagnostic value of exosomes in pancreatic cancer as well as the emerging use of lab-on-a-chip (LOC) technologies aiming to streamline exosome isolation and analysis.
Förderung
- European Research Council
Zitieren
APA
Chronopoulos, A., Lieberthal, T. J., & Hernández, A. E. D. R. (2017). Exosomes as a platform for ‘liquid biopsy’ in pancreatic cancer. Convergent Science Physical Oncology. https://doi.org/10.1088/2057-1739/aa5beb
Vancouver
Chronopoulos A, Lieberthal TJ, Hernández AEDR. Exosomes as a platform for ‘liquid biopsy’ in pancreatic cancer. Convergent Science Physical Oncology. 2017. doi:10.1088/2057-1739/aa5beb
BibTeX
@article{Chronopoulos2017,
author = {Chronopoulos, Antonios and Lieberthal, Tyler J and Hernández, Armando E del Río},
title = {Exosomes as a platform for ‘liquid biopsy’ in pancreatic cancer},
journal = {Convergent Science Physical Oncology},
year = {2017},
doi = {10.1088/2057-1739/aa5beb}
}
EUVIMED